Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From InflaRx N.V.

AstraZeneca Moves To Join Invyvid In COVID-19 Prevention

The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.

Commercial Companies

InflaRx Undaunted By Dermatology Rivals

The group says INF904 can make billions in two highly competitive skin diseases, but this looks optimistic.

Clinical Trials Commercial

InflaRx Picks Outcomes-Based Reimbursement For COVID-19 Drug

The model, more common with high-cost gene therapies, is designed to de-risk use of the drug for hospitals in the event that patients with COVID-19-related ARDS do not survive.

Coronavirus COVID-19 Respiratory

Scrip Asks...What Does 2024 Hold For Biopharma? Part 2: The Funding Environment, M&A And Partnering

Biotech entrepreneurs tend to be an optimistic group, and there were many pockets of hope for 2024. However, the consensus remains that depressed valuations and paucity of fresh funds will continue to pose a challenge for the sector, and companies will need to prioritize carefully and work even harder to demonstrate and create value.

Scrip Asks Financing
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • InflaRx GmbH
UsernamePublicRestriction

Register